

May 16, 2016



Dermata Therapeutics, LLC Announces Initiation of Phase 1 Pharmacokinetic Study

SAN DIEGO, May 16, 2016 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, today announced the initiation of their first in human, Phase 1 Pharmacokinetic Study, with their lead compound, DMT210. The Phase 1 Study is primarily designed to evaluate the pharmacokinetics and safety of DMT210, while also allowing early assessment of DMT210's clinical activity in patients with moderate-to-severe acne rosacea. The treatment will be administered twice daily for 28 days in two clinical sites, and Dermata plans to have top line results in the third quarter of this year.



"This marks an exciting time for Dermata, and DMT210, as it will be the first real test of this novel compound in patients," states Gerald T. Proehl, President and CEO of Dermata. "It seems like every day we are learning more about the broad capabilities of this unique product and are eager to progress our programs towards making DMT210 available for patients suffering from rosacea and other dermatological diseases."

About DMT210: DMT210 is a topical gel, containing a new chemical entity (NCE), which belongs to a new class of compounds called Isoprenylcysteines. This NCE is a G-protein modulator, designed as a structural mimic of the amino acid tail found at the C-terminus of G-proteins to reduce inflammation and erythema by blocking multiple cell signaling pathways. Because of DMT210's effect on multiple inflammatory pathways, Dermata plans to leverage this compound by developing it for multiple diseases.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. They have a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, acne vulgaris, atopic dermatitis and ocular rosacea. To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.

CONTACT: Dermata Contact
Gerald T. Proehl
President and CEO
858.223.0888
gproehl@dermatarx.com

Logo - <https://photos.prnewswire.com/prnh/20160512/367116LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-announces-initiation-of-phase-1-pharmacokinetic-study-300267926.html>

SOURCE Dermata Therapeutics, LLC